Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA | P42336 | 13/20 | 0.34 |
| ▸ | MTOR | P42345 | 13/20 | 0.34 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.34 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.34 |
| ▸ | MAOB | P27338 | 2/20 | 0.33 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.32 |
| ▸ | RAF1 | P04049 | 1/20 | 0.32 |
| ▸ | ABL1 | P00519 | 2/20 | 0.31 |
| ▸ | SMPD3 | Q9NY59 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16754514 | 1.00 | PIK3CA (0.34) | PIK3CAMTORPIK3CDPIK3CGMAOB | |
| SCHEMBL16754425 | 1.00 | PIK3CA (0.34) | PIK3CAMTORPIK3CDPIK3CGMAOB | |
| SCHEMBL19689734 | 0.92 | RAF1 (0.33) | FFAR4RAF1ABL1 | |
| SCHEMBL19689733 | 0.92 | RAF1 (0.33) | FFAR4RAF1ABL1 | |
| SCHEMBL16238670 | 0.87 | GRM5 (0.34) | FFAR4RAF1 | |
| SCHEMBL16754361 | 0.85 | RAF1 (0.36) | MAOBRAF1 | |
| SCHEMBL16754360 | 0.85 | RAF1 (0.36) | MAOBRAF1 | |
| SCHEMBL16754334 | 0.85 | RAF1 (0.36) | MAOBRAF1 | |
| SCHEMBL16754408 | 0.85 | PIK3CA (0.39) | PIK3CAMTORPIK3CDPIK3CGABL1 | |
| SCHEMBL17778246 | 0.83 | PIK3CA (0.33) | PIK3CAMTORSMPD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150152108-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | GLAXOSMITHKLINE LLC | 2015-06-04 | — | — | US | claimed |
| US-10590135-B2 | Substituted bridged urea analogs as sirtuin modulators | GLAXOSMITHKLINE LLC (US) | 2020-03-17 | — | — | US | disclosed |
| US-20170355705-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2017-12-14 | — | — | US | disclosed |
| US-20170355697-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | GLAXOSMITHKLINE LLC | 2017-12-14 | — | — | US | disclosed |
| US-9834558-B2 | Substituted bridged urea analogs as sirtuin modulators | GLAXOSMITHKLINE LLC (US) | 2017-12-05 | — | — | US | disclosed |
| EP-3221312-A2 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | Glaxosmithkline LLC (US) | 2017-09-27 | — | — | EP | disclosed |
| WO-2016081692-A2 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | GLAXOSMITHKLINE LLC (US) | 2016-05-26 | — | — | WO | disclosed |
| US-20150152108-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | GLAXOSMITHKLINE LLC | 2015-06-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150152108-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | SIRT1, SIRT3, SIRT2 | PIK3CA 3691/4885MTOR 433/4885PIK3CD 3327/4885 |
| US-20170355705-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | SIRT1, SIRT3, SIRT2 | PIK3CA 4059/4885MTOR 395/4885PIK3CD 3771/4885 |
| US-20170355697-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | SIRT1, SIRT3, SIRT2 | PIK3CA 3691/4885MTOR 433/4885PIK3CD 3327/4885 |
| US-10590135-B2 | Substituted bridged urea analogs as sirtuin modulators | SIRT1, SIRT3, SIRT2 | PIK3CA 3691/4885MTOR 433/4885PIK3CD 3327/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.